Drug Trial Radar · NCT05701306
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 28, 2023
Primary completion
Jun 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Suzhou Yasheng Pharmaceutical Co., Ltd.
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open, non-randomized Phase Ib-II trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory neuroblastoma or solid tumors.
Conditions
- Neuroblastoma
- Solid Tumor
Interventions
APG-115Drug
Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
APG-2575Drug
Orally once a day (QD) for 21 days, 21 days as a cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (Phase I)Time frame: Up to 21 days
- Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0Time frame: Up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Tongji Hospital, Huazhong University of Science and Technology (HUST)
Wuhan, Hubei, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.